Lyra Therapeutics To Present Lantern Phase 2 Study Results For Lyr 210 In Oral Presentation At Cosm 2021 Virtual

 Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that the company will present Phase 2 results from the LANTERN study for LYR-210, the company’s lead product candidate for chronic rhinosinusitis, at the Combined Otolaryngology Spring Meetings (COSM) 2021, taking place as a virtual event on April 7-11, 2021.

The oral presentation for LYR-210 will be featured in a COSM 2021 Virtual session on April 11. A clinical presentation of this data will be made available on Lyra’s website.

Oral Presentation Details:

Title: Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study

Date and Time: Sunday, April 11 at 2:36 p.m. CT

Location: Room A

Presenting Author: Anders Cervin, MD, University of Queensland Centre for Clinical Research, Royal Brisbane & Women’s Hospital Campus, Herston, QLD, Australia